Last reviewed 2026-04-23 · How we verify

MCV-ACYW135 Vaccine Group

MCV-ACYW135 is a meningococcal conjugate vaccine that stimulates immune response against serogroups A, C, Y, and W-135 of Neisseria meningitidis.

MCV-ACYW135 is a meningococcal conjugate vaccine that stimulates immune response against serogroups A, C, Y, and W-135 of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

At a glance

Mechanism of action

The vaccine contains polysaccharide capsules from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This induces production of bactericidal antibodies against the targeted serogroups, providing protection against invasive meningococcal disease caused by these pathogens.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135

Common side effects

• Injection site pain/erythema
• Fever
• Myalgia
• Headache

Key clinical trials

• Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine (PHASE3)
• A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MCV-ACYW135 Vaccine Group CI brief — competitive landscape report
• MCV-ACYW135 Vaccine Group updates RSS · CI watch RSS
• Beijing Minhai Biotechnology Co., Ltd portfolio CI